1. Scrip
  2. >>COVID-19

Coronavirus Update: J&J’s Single Dose Stands Out From COVID Vaccine Crowd

Phase III Planned For September

 
• By Scrip Team

J&J is a few months behind companies like Moderna, Pfizer and AstraZeneca in the race to develop a vaccine, but a safe and effective single dose immunization would be a game changer.

Manchester_Metro
Manchester, UK: restrictions on social gatherings were reintroduced in the city after rates of transmission began rising again • Source: Shutterstock

Johnson & Johnson has presented data showing its COVID-19 vaccine candidate provides protection for animals with a single dose, and has now progressed into Phase I/II human studies.

The data, published in Nature show its investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by neutralizing antibodies, and prevented subsequent infection by providing complete

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.